Ebola Antibody Vaccine Prophylaxis. Phase IIa pilot study evaluating the efficacy of a post-exposure prophylaxis strategy using monoclonal antibodies and a vaccine in high-risk contacts of Ebola virus disease.

  • Funded by Agence nationale de recherche sur le sida et les hépatites virale [National Agency for AIDS Research] (ANRS)
  • Total publications:0 publications

Grant number: ANRS0006s

Grant search

Key facts

  • Disease

    Ebola
  • Start & end year

    2021
    2026
  • Known Financial Commitments (USD)

    $551,700
  • Funder

    Agence nationale de recherche sur le sida et les hépatites virale [National Agency for AIDS Research] (ANRS)
  • Research Location

    99
  • Lead Research Institution

    N/A
  • Research Priority Alignment

    N/A
  • Research Category

    Therapeutics research, development and implementation
  • Research Subcategory

    Phase 2 clinical trial
  • Special Interest Tags

    N/A
  • Study Type

    Clinical
  • Clinical Trial Details

    Not applicable
  • Broad Policy Alignment

    Pending
  • Age Group

    Unspecified
  • Vulnerable Population

    Unspecified
  • Occupations of Interest

    Unspecified

Abstract

N/A